BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 27893589)

  • 21.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
    Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Koerber SA; Utzinger MT; Kratochwil C; Kesch C; Haefner MF; Katayama S; Mier W; Iagaru AH; Herfarth K; Haberkorn U; Debus J; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1943-1948. PubMed ID: 28619734
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 25. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological predictors of positive
    Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
    Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
    Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
    Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
    Lengana T; van de Wiele C; Lawal I; Maes A; Ebenhan T; Boshomane T; Zeevaart JR; Ankrah A; Mokgoro N; Vorster M; Sathekge M
    Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET/CT With
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
    J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
    Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
    Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.